Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 1.00 |
| ▸ | MMP1 | P03956 | 13/20 | 0.78 |
| ▸ | MMP2 | P08253 | 13/20 | 0.78 |
| ▸ | MMP9 | P14780 | 13/20 | 0.78 |
| ▸ | MAOA | P21397 | 4/20 | 0.70 |
| ▸ | MAOB | P27338 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.62 |
| ▸ | TOP2A | P11388 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL707945 | 1.00 | EGFR (1.00) | EGFRMMP1MMP2MMP9MAOA | |
| SCHEMBL707632 | 0.90 | EGFR (0.81) | EGFRMMP1MMP2MMP9MAOA | |
| SCHEMBL707633 | 0.90 | EGFR (0.81) | EGFRMMP1MMP2MMP9MAOA | |
| SCHEMBL705745 | 0.88 | MMP1 (1.00) | EGFRMMP1MMP2MMP9MAOA | |
| SCHEMBL705746 | 0.88 | MMP1 (1.00) | EGFRMMP1MMP2MMP9MAOA | |
| N-(4-Fluorophenyl)Cinnamamide SCHEMBL7707929 | 0.85 | MMP1 (1.00) | EGFRMMP1MMP2MMP9MAOA | |
| N-(4-Fluorophenyl)Cinnamamide SCHEMBL9989034 | 0.85 | MMP1 (1.00) | EGFRMMP1MMP2MMP9MAOA | |
| N-Phenylcinnamamide SCHEMBL3667414 | 0.83 | MMP1 (1.00) | EGFRMMP1MMP2MMP9MAOA | |
| N-Phenylcinnamamide SCHEMBL4205896 | 0.83 | MMP1 (1.00) | EGFRMMP1MMP2MMP9MAOA | |
| SCHEMBL11590995 | 0.83 | EGFR (0.92) | EGFRMMP1MMP2MMP9MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-8124602-B2 | Compounds for the treatment of multi-drug resistant bacterial infections | ASTRAZENECA AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| EP-2289890-A1 | Compounds for the treatment of multi-drug resistant bacterial infections | AstraZeneca AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| US-7875715-B2 | 6-[({1-[2-(7-methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; antibacteria; methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative staphylococci (MRCNS), penicillin-resistant Streptococcus pneumoniae | ASTRAZENECA AB (SE) | 2011-01-25 | — | — | US | disclosed |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
| US-20100056502-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| EP-2125813-A2 | COMPOUNDS | Glaxo Group Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008116815-A2 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056502-A1 | COMPOUNDS | NRDC, NACA, NAA50 | EGFR 1531/4885MMP1 2401/4885MMP2 1766/4885 |
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | EGFR 2504/4885MMP1 368/4885MMP2 853/4885 |
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | EGFR 2504/4885MMP1 368/4885MMP2 853/4885 |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | EGFR 2504/4885MMP1 368/4885MMP2 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.